WORLD PEPTIDEFOUNDATION

archived version — not current

This is a permanent, read-only archive of this profile's public content as it existed on 2026-09-27. It does not reflect the current, live profile. View the current profile.

Desmopressin

Snapshot captured 2026-09-27 — Evidence added or removed

Overview

Desmopressin is a synthetic analog of arginine vasopressin modified by deamination at position 1 and D-arginine at position 8. It preferentially activates renal V2 receptors, increasing collecting-duct water reabsorption through aquaporin-2 trafficking; V2-mediated endothelial release of von Willebrand factor and factor VIII underlies selected haemostatic uses. Clinical effects and risks differ materially by indication, dose, route, formulation, renal function, fluid intake, age, and concomitant medicines.

Evidence quality

The 25-source governed corpus spans randomized trials and systematic reviews in nocturia and nocturnal enuresis, central nervous system and renal contexts, perioperative or uremic bleeding, haemophilia, paediatric pharmacokinetics, and prevention of rapid sodium overcorrection. Safety-specific reviews address hyponatremia and adverse effects in bleeding disorders. PubMed identity, bibliographic metadata, DOI/PMID, desmopressin relevance, source status, and duplication were verified. Study-design grades remain provisional and indication-specific; source identity verification is not a substitute for claim-level clinical adjudication.

Safety concerns

Hyponatremia, water intoxication, seizures, and other serious consequences can occur, especially with excess fluid intake, renal impairment, older age, interacting medicines, inappropriate route or dose, or illness affecting fluid and electrolyte balance. Intranasal, oral, sublingual, and injectable products are not dose-equivalent. Evidence for particular haemostatic and perioperative uses is mixed and context-dependent. Current product labeling controls sodium monitoring, fluid restriction, contraindications, warnings, and approved indications.

Citations as of this version

Regulatory status as of this version

  • United States (FDA — DDAVP): approved — DDAVP desmopressin acetate tablets are FDA-approved as antidiuretic replacement therapy in central diabetes insipidus and for management of temporary polyuria and polydipsia following head trauma or pituitary-region surgery, subject to current labeling.
  • United States (FDA — DESMODA): approved — DESMODA desmopressin acetate oral solution is FDA-approved for antidiuretic replacement therapy in patients with central diabetes insipidus (arginine vasopressin deficiency), according to its current product labeling.

Content hash: 68601b32079cf2c6380fa3eb6e417b0f9731cecb606ab098886aa77c1af13d9d

All archived versions